NASDAQ: FREQFrequency Therapeutics Inc Stock
$0.36-0.02 (-5.26%)
Updated Sep 25, 2023
FREQ Price
$0.36
Fair Value Price
$1.52
Market Cap
$13.15M
52 Week Low
$0.33
52 Week High
$5.59
P/E
-0.19x
P/B
0.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$67.25M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.75
Operating Cash Flow
-$50M
Beta
1
Next Earnings
Nov 6, 2023
Ex-Dividend
N/A
Next Dividend
N/A
FREQ Overview
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FREQ scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FREQ ($0.36) is undervalued by 76.26% relative to our estimate of its Fair Value price of $1.52 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FREQ ($0.36) is significantly undervalued by 76.26% relative to our estimate of its Fair Value price of $1.52 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FREQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FREQ due diligence checks available for Premium users.
Be the first to know about important FREQ news, forecast changes, insider trades & much more!
FREQ News
Valuation
FREQ fair value
Fair Value of FREQ stock based on Discounted Cash Flow (DCF)
Price
$0.36
Fair Value
$1.52
Undervalued by
76.26%
FREQ ($0.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FREQ ($0.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FREQ is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FREQ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.19x
Industry
12.93x
Market
14.28x
FREQ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.29x
Industry
5.09x
FREQ is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FREQ's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.8M
Profit Margin
0%
FREQ's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$79.4M
Liabilities
$34.0M
Debt to equity
0.75
FREQ's short-term assets ($48.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FREQ's short-term assets ($48.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FREQ's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.4M
Investing
$19.2M
Financing
-$11.7M
FREQ's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FREQ vs Biotech Stocks
Frequency Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.